Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingEnovis Corporation (the “Company”, “Enovis”, “we” or “us”) is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery or injury or from degenerative disease, enabling people to regain or maintain their natural motion.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q2 2026 · $426.1MThe company’s own SEC segment disclosure.
- Surgical$137.8M32%
- Bracing And Support$127.6M30%
- Prevention And Recovery$101.0M24%
- Other Prevention And Recovery$59.6M14%
Enovis Corporation (ENOV) reported revenue of $589M in Q1 2026 (quarter ended April 3, 2026), up 5.4% from the same quarter a year earlier. That came with a gross margin of 62% and net loss of $8.8M. For the full year FY2025, revenue was $2.25B (+6.7% year on year) and net income −$1.18B. Its largest product in 2026-Q2 was Surgical at $138M, 32% of the disclosed total, just ahead of Bracing And Support at 30%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.